The Parkinson Progression Marker Initiative (PPMI)

[1]  J. Jankovic,et al.  CSF Aβ42 and tau in Parkinson's disease with cognitive impairment , 2010, Movement disorders : official journal of the Movement Disorder Society.

[2]  A. Stefani,et al.  Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature. , 2010, Brain : a journal of neurology.

[3]  J. Trojanowski,et al.  CSF amyloid β 1-42 predicts cognitive decline in Parkinson disease , 2010, Neurology.

[4]  J. Seibyl,et al.  The role of the core imaging laboratory in multicenter trials. , 2010, Seminars in nuclear medicine.

[5]  W. Poewe,et al.  Rationale for delayed‐start study of pramipexole in Parkinson's disease: The PROUD study , 2010, Movement disorders : official journal of the Movement Disorder Society.

[6]  Carlo Colosimo,et al.  Task force report on scales to assess dyskinesia in Parkinson's disease: Critique and recommendations , 2010, Movement disorders : official journal of the Movement Disorder Society.

[7]  P. Snyder,et al.  The Alzheimer's Disease Neuroimaging Initiative: Perspectives of the Industry Scientific Advisory Board , 2010, Alzheimer's & Dementia.

[8]  C. Jack,et al.  Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects , 2010, Alzheimer's & Dementia.

[9]  J. Morris,et al.  Clinical core of the Alzheimer's disease neuroimaging initiative: Progress and plans , 2010, Alzheimer's & Dementia.

[10]  Mark E. Schmidt,et al.  The Alzheimer's Disease Neuroimaging Initiative: Progress report and future plans , 2010, Alzheimer's & Dementia.

[11]  C. Jack,et al.  Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade , 2010, The Lancet Neurology.

[12]  Werner Poewe,et al.  A double-blind, delayed-start trial of rasagiline in Parkinson's disease. , 2009, The New England journal of medicine.

[13]  D. Berg,et al.  Progression of Parkinson's disease in the clinical phase: potential markers , 2009, The Lancet Neurology.

[14]  C. Tanner,et al.  A longitudinal program for biomarker development in Parkinson's disease: A feasibility study , 2009, Movement disorders : official journal of the Movement Disorder Society.

[15]  Min Shi,et al.  Biomarker discovery in neurodegenerative diseases: A proteomic approach , 2009, Neurobiology of Disease.

[16]  B. Mollenhauer,et al.  Neurochemical biomarkers in the differential diagnosis of movement disorders , 2009, Movement disorders : official journal of the Movement Disorder Society.

[17]  H. Soininen,et al.  Safety of lumbar puncture procedures in patients with Alzheimer's disease. , 2009, Current Alzheimer research.

[18]  M. B. Spraker,et al.  High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease , 2009, Neurology.

[19]  R. Petersen,et al.  Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects , 2009, Annals of neurology.

[20]  D. Jennings,et al.  Can we image premotor Parkinson disease? , 2009, Neurology.

[21]  A. Schapira,et al.  Why have we failed to achieve neuroprotection in Parkinson's disease? , 2008, Annals of neurology.

[22]  D. Jennings,et al.  Biomarkers for Parkison's disease: Tools to assess Parkinson's disease onset and progression , 2008, Annals of neurology.

[23]  Eugene M. Johnson,et al.  MIXED LINEAGE KINASE INHIBITOR CEP- 1347 FAILS TO DELAY DISABILITY IN EARLY PARKINSON DISEASE , 2008, Neurology.

[24]  H. Braak,et al.  Invited Article: Nervous system pathology in sporadic Parkinson disease , 2008, Neurology.

[25]  P. Riederer,et al.  Early Detection of Parkinson’s Disease: Unmet Needs , 2008, Neurodegenerative Diseases.

[26]  C. Klein,et al.  Parkinson disease, 10 years after its genetic revolution: Multiple clues to a complex disorder , 2007, Neurology.

[27]  David Eidelberg,et al.  Assessment of the progression of Parkinson's disease: a metabolic network approach , 2007, The Lancet Neurology.

[28]  Dag Aarsland,et al.  Gray matter atrophy in Parkinson disease with dementia and dementia with Lewy bodies , 2007, Neurology.

[29]  J. Growdon,et al.  Molecular markers of early Parkinson's disease based on gene expression in blood , 2007, Proceedings of the National Academy of Sciences.

[30]  A. Schapira,et al.  TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial , 2006, The Lancet Neurology.

[31]  J. Langston,et al.  The parkinson's complex: Parkinsonism is just the tip of the iceberg , 2006, Annals of neurology.

[32]  D. Allsop,et al.  Detection of oligomeric forms of α‐synuclein protein in human plasma as a potential biomarker for Parkinson's disease , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[33]  K. Gwinn‐Hardy,et al.  The role of radiotracer imaging in Parkinson disease , 2005, Neurology.

[34]  A. Schapira.  Disease modification in Parkinson's disease , 2004, The Lancet Neurology.

[35]  Claude Nahmias,et al.  Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL‐PET study , 2003, Annals of neurology.

[36]  Joel S Perlmutter,et al.  Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. , 2002, Archives of neurology.

[37]  M. Brin,et al.  Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. , 1993, The New England journal of medicine.

[38]  A. Lees,et al.  Striatonigral degeneration. A clinicopathological study. , 1990, Brain : a journal of neurology.

[39]  J. Jankovic.  Lower body (vascular) parkinsonism. , 1990, Archives of neurology.